Search Within

Matthew J Matasar

  1. "Blood"
  2. "Maria Palomba"
  3. "Anas Younes"
  4. "John Gerecitano"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (4)
Groups
  1. Center for Hematologic Malignancies (17)
  2. Department of Medicine (17)
  3. Executive Committee, Center for Hematologic Malignancies (17)
  4. Hematologic Malignancies, Division of (17)
  5. Lymphoma (17)
  6. Survivorship Research (17)

More Groups

People
  1. Anas Younes (17)
  2. Andrew Zelenetz (17)
  3. Ariela Noy (17)
  4. John Gerecitano (17)
  5. Maria Palomba (17)
  6. Alison Moskowitz (16)

More People

Years
  1. 2019 (1)
  2. 2018 (1)
  3. 2017 (6)
  4. 2016 (4)
  5. 2015 (2)
  6. 2014 (2)

More Years

Publications
  1. Blood (17)
Publishers
  1. American Society of Hematology (17)

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schòˆder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Veliparib (ABT-888), bendamustine, and rituximab (VBR) is well tolerated and efficacious in patients with lymphoma: Final analysis of a phase 1b clinical trial of VB and a cohort expansion of VBR in patients with B-cell lymphoma
    Meeting Abstract

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Younes, A.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Identification of actionable genomic alterations across different lymphoma histologies using a comprehensive next generation genomic sequencing clinical assay
    Meeting Abstract

    Batlevi, C.; Moskowitz, C. H.; Zelenetz, A. D.; Horwitz, S. M.; Palomba, L.; Gerecitano, J. F.; Copeland, A. R.; Hamlin, P.; Matasar, M. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
    Blood (2013)

    Fulltext@MSK | Save